Alcohol Dependence in Primary and Specialist Care in Europe - Data set

The dataset refers to the 'Alcohol Dependence in Primary and Specialist Care in Europe' study.<br><br>All data were collected in primary and specialized health care settings in 6/8 European countries. Please see the references for more details.<br><br>Primary care: Germany, Hungary, Italy, Latvia, Poland, Spain<br>Specialized care: Austria, France, Germany, Hungary, Italy, Latvia, Poland, Spain<br><br>The codebook includes all variables including variable labels. More information on design, sampling, and data collection can be found in the references.<br><br>For any question, please contact Jakob Manthey.<br

Data_Sheet_1_Substance use disorders and COVID-19: reflections on international research and practice changes during the “poly-crisis”.pdf

Since March 2020, the COVID-19 pandemic has had a disproportionately high toll on vulnerable populations, coinciding with increased prevalence of alcohol-and drug-related deaths and pre-existing societal issues such as rising income inequality and homelessness. This poly-crisis has posed unique challenges to service delivery for people with substance use disorders, and innovative approaches have emerged. In this Perspectives paper we reflect on the poly-crisis and the changes to research and practice for those experiencing substance use disorders, following work undertaken as part of the InterGLAM project (part of the 2022. Lisbon Addictions conference). The authors, who were part of an InterGLAM working group, identified a range of creative and novel responses by gathering information from conference attendees about COVID-19-related changes to substance use disorder treatment in their countries. In this paper we describe these responses across a range of countries, focusing on changes to telehealth, provision of medications for opioid use disorder and alcohol harm reduction, as well as changes to how research was conducted. Implications include better equity in access to technology and secure data systems; increased prescribed safer supply in countries where this currently does not exist; flexible provision of medication for opioid use disorder; scale up of alcohol harm reduction for people with alcohol use disorders; greater involvement of people with lived/living experience in research; and additional support for research in low- and middle-income countries. The COVID-19 pandemic has changed the addictions field and there are lessons for ongoing and emerging crises.</p

Data_Sheet_2_Substance use disorders and COVID-19: reflections on international research and practice changes during the “poly-crisis”.docx

Since March 2020, the COVID-19 pandemic has had a disproportionately high toll on vulnerable populations, coinciding with increased prevalence of alcohol-and drug-related deaths and pre-existing societal issues such as rising income inequality and homelessness. This poly-crisis has posed unique challenges to service delivery for people with substance use disorders, and innovative approaches have emerged. In this Perspectives paper we reflect on the poly-crisis and the changes to research and practice for those experiencing substance use disorders, following work undertaken as part of the InterGLAM project (part of the 2022. Lisbon Addictions conference). The authors, who were part of an InterGLAM working group, identified a range of creative and novel responses by gathering information from conference attendees about COVID-19-related changes to substance use disorder treatment in their countries. In this paper we describe these responses across a range of countries, focusing on changes to telehealth, provision of medications for opioid use disorder and alcohol harm reduction, as well as changes to how research was conducted. Implications include better equity in access to technology and secure data systems; increased prescribed safer supply in countries where this currently does not exist; flexible provision of medication for opioid use disorder; scale up of alcohol harm reduction for people with alcohol use disorders; greater involvement of people with lived/living experience in research; and additional support for research in low- and middle-income countries. The COVID-19 pandemic has changed the addictions field and there are lessons for ongoing and emerging crises.</p

Characteristics of suicide subjects.

*<p>We observed statistically significant difference regarding gender between cases and controls (47.11% males for controls, <i>p</i><0.001 vs. suicides)</p>**<p>We observed statistically significant difference regarding age between cases and controls (mean = 45.70, SD = 14.91 for controls, <i>p</i> = 0.003 vs. suicides)</p

Characteristics of suicide subjects from the replication cohort.

<p>Characteristics of suicide subjects from the replication cohort.</p

Distribution of genotypes and analysis of the association between rs6943555 and suicide.

<p>P values <0.05 were <b>boldfaced</b>¹ comparison with all controls; ² comparison with controls with BDI ≤ 11, HWE - Hardy-Weinberg equilibrium, ³for 8 subjects from suicide cohort II there were no data on blood ethanol concentration</p

Characteristics of suicide subjects.

<p>Characteristics of suicide subjects.</p

Age and sex adjusted mean quintile of alcohol consumption per day per kg of body weight vs. the rs6943555 genotype encoded as the number of the A alleles among 3830 WOBASZ subjects.

<p>Vertical bars indicate 95% confidence intervals.</p

Distribution of genotypes and analysis of the association between rs9939609 and suicide.

<p><i>P</i> values <0.05 are <b>boldfaced</b>; <i>P_cor</i> – <i>P</i> values corrected for multiple testing with Bonferroni method;</p><p>* comparison with controls.</p><p>Distribution of genotypes and analysis of the association between rs9939609 and suicide.</p